Protocol Ledger

NCT05564052 · Phase II · COMPLETED

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Interventional Phase II clinical trial protocol NCT05564052 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-06 Enrollment: 36 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05564052
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05564052
Protocol FieldVerified Registry Value
NCT IdentifierNCT05564052
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment36 participants (ACTUAL)
Registered Start Date2022-12-06
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI